Q
QuantAbundanceAbundance, Quantified.

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

30,601 signal articles · 137 in last 24h · 155,347 total before filter · latest 1h ago
137last 24h
852last 7d
146● bullish (7d)
90● bearish (7d)
214publishers
AllMacro192Earnings102M&A125Regulatory20Product22Analyst19
✕ clear all filterssentiment: neutralSentiment:bullishneutralbearishshow all (incl. clickbait)
European Stocks Mixed, Chip Stocks Slide
The Wall Street Journal11d agoneutral
European Stocks Mixed, Chip Stocks Slide

STOCKS 0720 GMT – European stocks largely are mixed at the open as chip stocks fall sharply on investor concerns the artificial-intelligence build-out will slow. Software and pharmaceutical names support the Europe-wide Stoxx 600, which trades flat.

Stock Market: Will S&P 500 Open Up or Down Today?
Benzinga Prediction Markets11d agoneutral
Stock Market: Will S&P 500 Open Up or Down Today?

The S&P 500 closed higher on Friday, surging 0.86% to close at 7,656.98, but U.S. stock futures were pointing lower early Monday as investors grappled with surging oil prices, elevated Treasury yields and a looming Federal Reserve interest-rate decision. The...

Anthropic Picks Nasdaq for Its $2 Trillion IPO, Tells Investors It Expects a Second Consecutive Profitable Quarter: Reports
Benzinga11d agoneutral
Anthropic Picks Nasdaq for Its $2 Trillion IPO, Tells Investors It Expects a Second Consecutive Profitable Quarter: Reports

Anthropic has reportedly selected Nasdaq as the venue for its planned initial public offering and has told a small group of investors it expects positive adjusted operating income for a second straight quarter. Nasdaq Wins Another Major AI Listing Anthropic is targeting an October listing on Nasdaq, Business Insider reported on Sunday, citing a person familiar with the matter. A listing there would also make the company eligible for inclusion in the Nasdaq 100 Index. The IPO could value Anthropi

Chevron Australia President on LNG outlook
Bloomberg11d agoneutralVIDEO
Chevron Australia President on LNG outlook

Balaji Krishnamurthy, President of Chevron in Australia, discusses the outlook for LNG supply and demand, and pricing levels, as energy disruptions continue on Middle East tensions. He speaks with Haslinda Amin, on the sidelines of Gastech in Bangkok, on "Bloomberg: The Asia Trade". Correct: video has been edited to fix the spelling of Bangkok in a segment.

Stock Futures Poised to Trade Ahead of Fed Rate Decision
Barrons.com12d agoneutral
Stock Futures Poised to Trade Ahead of Fed Rate Decision

Stock futures are set to begin trading later on Sunday ahead of the Federal Reserve’s interest rate decision this week. The yield on 10-year Treasury notes hit 4.97%, the highest since October 2023, and the 30-year bond yield rose above 5.35% for the first time since 2007. Markets largely expect Fed Chairman Kevin Warsh will deliver a rate increase after the Federal Open Market Committee meets this Tuesday and Wednesday.

The Week Everybody Started Talking About AI Doomsday
The Wall Street Journal12d agoneutral
The Week Everybody Started Talking About AI Doomsday

It started Tuesday when an Anthropic researcher told The Wall Street Journal he was quitting. Shortly after, a current Anthropic researcher took to X to confirm the sentiment, adding he believes the risk the human race will go extinct in the next 10 years is higher than 10%. My colleagues Amrith Ramkumar, Lindsay Ellis and I spoke with lawmakers, church leaders and even one filmmaker who are now being called to answer some hard questions: Is this real?

Pfizer Makes an Unusual Enemy in $2 Billion Fight Over Unwanted Covid-19 Vaccines
The Wall Street Journal12d agoneutral
Pfizer Makes an Unusual Enemy in $2 Billion Fight Over Unwanted Covid-19 Vaccines

Pfizer is taking aim at an unusual target in its quest to get paid for millions of unwanted Covid-19 vaccines: air-traffic controllers. The drug giant has pursued European governments seeking to enforce pandemic-era contracts to buy billions of dollars’ worth of vaccines that haven’t yet been made and are no longer needed. In April, it won a yearslong legal fight to hold Poland and Romania to deals for more than 90 million shots.